EUCTR2010-020363-21-IT进行中（未招募）不适用
An open-label, phase 2/3, treatment-option protocol of brentuximab vedotin in patients with progression of Hodgkin lymphoma - ND
SEATTLE GENETICS INC.0 个研究点目标入组 80 人开始时间: 2010年9月28日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patients who met all inclusion/exclusion criteria for and participated in the SGN35-005 clinical study. 2. Patients who were treated with placebo in the SGN35-005 clinical study after autologous hematopoietic stem cell transplantation (ASCT) and experienced progression of HL based on the Revised Response Criteria for Malignant Lymphoma (Cheson 2007) as defined by protocol in study SGN35-005. 3. Age greater than or equal to 18 years. 4. An Eastern Cooperative Oncology Group (ECOG) performance status =2. 5. Patients must have completed any previous treatment with radiation, chemotherapy, biologics and/or investigational agents at least 4 weeks prior to the first dose of SGN-35. 6. Females of childbearing potential must have a negative serum or urine ß-hCG pregnancy test result within 7 days prior to the first dose of brentuximab vedotin. Females of non-childbearing potential are those who are postmenopausal for more than 1 year or who have had a bilateral tubal ligation or hysterectomy. 7. Both females of childbearing potential and males who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 30 days following the last dose of study drug. 8. The following baseline laboratory values are required: absolute neutrophil count (ANC) =1000/µL, platelets =50,000/µL, bilirubin =1.5 x upper limit of normal (ULN) or =3 x ULN for patients with Gilbert’s disease, serum creatinine =1.5 x ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =2.5 x ULN. 9. Patients or their legally authorized representative must provide written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Any Grade 3 viral, bacterial, or fungal infection requiring treatment with therapy within 1 week prior to the first study dose. 2. Patients with = Grade 2 peripheral neuropathy. 3. History of another primary malignancy that has not been in remission for at least 3 years. (The following are exempt from the 3-year limit: nonmelanoma skin cancer, fully excised melanoma in situ [Stage 0], curatively treated localized prostate cancer, and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on PAP smear.) 4. Known cerebral/meningeal disease. 5. Current therapy with other systemic anti-neoplastic or investigational agents. 6. Women who are pregnant or lactating. 7. Patients with a known hypersensitivity to any excipient contained in the drug formulation. 8. Patients with dementia or an altered mental state that would preclude the understanding and rendering of informed consent. 9. Patients who are eligible for participation in other clinical studies of brentuximab vedotin at their institution.
研究者
相似试验
进行中（未招募）
1 期
An open-label, phase 2/3, treatment-option protocol ofbrentuximab vedotin in patients with progression of HodgkinlymphomaPatients who were on the placebo arm and experienced progression of HL whileparticipating in the SGN35-005 clinical studyMedDRA version: 12.1Level: LLTClassification code 10020328Term: Hodgkin's lymphomaEUCTR2010-020363-21-FRSeattle Genetics, Inc.80
进行中（未招募）
1 期
eoadjuvant L19IL2/L19TNF- Pivotal studyMalignant melanoma of the skin in patients with locally advanced and fully resectable melanoma with/without prior therapy and presence of injectable cutaneous and/or subcutaneous or nodal lesionsMedDRA version: 21.1Level: PTClassification code: 10025670Term: Malignant melanoma stage III Class: 100000004864CTIS2024-515749-40-00Philogen S.p.A.236
进行中（未招募）
1 期
Efficacy study of L19IL2/L19TNF neoadjuvant intratumoral treatment followed by surgery versus surgery alone in patients with a specific type of melanoma.Malignant melanoma of the skin in patients with locally advanced and fully resectable melanoma with/without prior therapy and presence of injectable cutaneous and/or subcutaneous or nodal lesions.MedDRA version: 21.1Level: PTClassification code 10025670Term: Malignant melanoma stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-002549-72-ITPHILOGEN S.P.A.214
进行中（未招募）
1 期
Study of safety, efficacy, pharmacokinetics and pharmacodynamics of APO-EPO versus Epogen®/Procrit® in patients with anemia and chronic kidney disease not yet on hemodialysisTreatment of anemia due to chronic kidney disease in patients not yet on hemodialysisMedDRA version: 15.1Level: LLTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 100000004857EUCTR2011-005058-70-SKAPOTEX Inc.196
进行中（未招募）
不适用
Study of safety, efficacy, pharmacokinetics and pharmacodynamics of APO-EPO versus Epogen®/Procrit® in patients with anemia and chronic kidney disease not yet on hemodialysisEUCTR2011-005058-70-HUAPOTEX Inc.196